Novavax, Inc. (NVAX)
| Market Cap | 1.65B |
| Revenue (ttm) | 1.12B |
| Net Income (ttm) | 440.30M |
| Shares Out | 162.94M |
| EPS (ttm) | 2.58 |
| PE Ratio | 3.93 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,229,166 |
| Open | 11.15 |
| Previous Close | 11.19 |
| Day's Range | 9.81 - 11.15 |
| 52-Week Range | 5.01 - 11.97 |
| Beta | 2.58 |
| Analysts | Hold |
| Price Target | 11.33 (+11.74%) |
| Earnings Date | Feb 26, 2026 |
About NVAX
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adoles... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for NVAX stock is "Hold." The 12-month stock price target is $11.33, which is an increase of 11.74% from the latest price.
News
What's Going On With Novavax Stock On Friday?
Novavax Inc. (NASDAQ: NVAX) shares are down on Friday, possibly on profit-taking after the stock rallied on Thursday following the company's announcement of its fourth-quarter and full-year 2025 finan...
Novavax: The Bear Case Is Broken, But The Bull Case Needs More Proof
Novavax (NVAX) has transitioned into a royalty-driven model, with Q4 profitability and 73% of revenue from licensing and royalties. NVAX's FY26 revenue guidance of $230M–$270M reflects cleaner, high-m...
Novavax to Participate in Upcoming Investor Conferences
GAITHERSBURG, Md., Feb. 26, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), today announced that it will participate in the following upcoming investor conferences: TD Cowen 46 th Annual Health Car...
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
Novavax, Inc. (NVAX) Q4 2025 Earnings Call Transcript
COVID-19 Vaccine Maker Novavax Swings To Profit As Sales Climb
Novavax Inc. (NASDAQ: NVAX) shares are up on Thursday following the company's announcement of its fourth-quarter and full-year 2025 financial results.
Novavax raises 2026 adjusted revenue outlook on strength in vaccine deals
Novavax raised its adjusted revenue forecast for 2026 on Thursday, as it expects milestone payments from vaccine supply and licensing deals to offset pressure from sagging demand.
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Pfizer agreement announced in January 2026 for non-exclusive license to utilize Matrix-M® in two infectious disease areas Multiple Material Transfer Agreements signed in 2025 and Q1 2026 with pharmace...
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
GAITHERSBURG, Md., Feb. 19, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter and full year 2025 financial results and operational highlights at 8:30 ...
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Moderna, Inc. and Novavax, Inc. have transitioned from pandemic-era highs to focusing on cost reduction, pipeline development, and a path to breakeven by 2028. NVAX leverages partnerships with Sanofi ...
Novavax Announces Entering into a License Agreement with Pfizer
Non-exclusive license allows for development by Pfizer to utilize Matrix-M ® for up to two disease areas with its products Provides Novavax with an upfront payment of $30 million with the potential fo...
Novavax enters license agreement with Pfizer for vaccine development
Novavax said on Tuesday it was entering into a licensing agreement with Pfizer to develop vaccine products for infectious diseases.
Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novavax, Inc. (NVAX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
GAITHERSBURG, Md., Jan. 7, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the 44th Annual J.P.
FDA Plans to Tighten Vaccine Approvals Weigh on These Stocks
A report that vaccine approvals could be set to get stricter is pressuring shares of major vaccine makers.
Vaccine stocks take a hit as FDA official points to link between COVID-19 vaccines and rare heart condition in young men
Memo also reportedly mentions vaccines for flu and pneumonia.
Moderna and Novavax Stocks Drop as FDA Proposes Stricter Vaccine Approvals
The FDA's top vaccine regulator outlines proposed changes to the vaccine evaluation process in an internal memo.
Novavax, Inc. (NVAX) Presents at Jefferies London Healthcare Conference 2025 Transcript
Novavax, Inc. ( NVAX) Jefferies London Healthcare Conference 2025 November 19, 2025 11:30 AM EST Company Participants Ruxandra Draghia-Akli - Executive VP and Head of Research & Development James Kel...
Shah Capital pushes for Novavax sale, warns of proxy fight
Shah Capital, Novavax's second-largest shareholder, is pressing the biotech's board to pursue strategic changes, including a potential sale, and warned it could launch a proxy fight if no progress is ...
Novavax to Participate in Jefferies London Healthcare Conference
GAITHERSBURG, Md. , Nov. 12, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that it will participate in the following upcoming investor conference: Jefferies London Healthcare Confe...
Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript
Novavax, Inc. ( NVAX) Q3 2025 Earnings Call November 6, 2025 8:30 AM EST Company Participants John Jacobs - President, CEO & Director Ruxandra Draghia-Akli - Executive VP and Head of Research & Devel...
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Total revenue of $70 million in the third quarter of 2025 Continued successful execution of Sanofi partnership with $225 million in milestones achieved year-to-date including $50 million earned on mar...
Novavax raises annual revenue forecast on strength of vaccine deals
Novavax raised its annual revenue forecast for the third time this year on Thursday, banking on milestone payments from vaccine supply and licensing deals such as with Japan's Takeda Pharmaceuticals.
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Novavax has successfully achieved U.S. BLA approval and completed both EU and U.S. marketing authorization transfers for Nuvaxovid™ to Sanofi in line with its CLA and its corporate strategy, securing ...
Novavax to Report Third Quarter 2025 Financial Results on November 6, 2025
GAITHERSBURG, Md. , Oct. 30, 2025 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its third quarter 2025 financial results and operational highlights at 8:30 a.m.
Novavax Executes Planned Site Consolidation, Further Reducing Cost Footprint in Line with Corporate Strategy
Agreements signed to transfer one U.S.-based facility and sell certain equipment netting $60 million in cash and resulting in future cash savings of $230 million Novavax headquarters to remain in Gait...